PeptiDream Inc.
https://www.peptidream.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PeptiDream Inc.
Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
Faster, Better? Fujitsu, Polarisqb 'Quantum-Inspired' Tech Speeds Discovery
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
Sosei Heptares Bags Second GPCR Targets Deal In A Month, With Takeda
The Japanese biotech agreed a multi-year, multi-target research collaboration and license deal with Takeda to discover and develop medicines that modulate GPCR targets, initially in GI.
Kleo Brings Small-Molecule Approach To IO With Three Technological Applications
Emerging Company Profile: Using IP licensed from Yale, Kleo is betting it can complement or replace existing immuno-oncology drugs, specifically Darzalex. In partnership with PeptiDream, it just unveiled its first candidate for clinical development.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity